Strategy to reduceE. colibacteraemia based on cohort data from a London teaching hospital
Authors:
- 20 February 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 94 (1110) , 212-215
Abstract
Background and aim In 2017, National Health Service Improvement set a 10% reduction target for Escherichia coli bacteraemia by 2018, followed by a 50% reduction in healthcare-associated Gram-negative bacteraemias by 2022. We analysed consecutive cases of E. coli bacteraemia and devised a strategy to achieve these targets. Methods From December 2012 to November 2013, demographic, clinical and microbiological data were prospectively collected on all patients with bacteraemia at the Royal London Hospital in East London, UK. Results There were 594 significant bacteraemic episodes and 207 (34.8%) were E. coli. Twenty-four (11.6%) of the E. coli isolates were extended spectrum beta-lactamase producers, 22 (10.6%) gentamicin resistant and 2 (1.0%) amikacin resistant. The three most common sites of infection were pyelonephritis 105 (56.7%), catheter-associated urinary tract infection 22 (10.6%), and other medical devices and procedures that cause bacteraemia 32 (15.5%). In the pyelonephritis group, trimethoprim resistance in urinary isolates was 16/47 (34.0%) compared with 3/47 (6.4%) for nitrofurantoin. Twelve months postbacteraemia, recurrent bacteraemia rates were 10/105 (9.5%). There were 44 medical device-associated E. coli bacteraemias, and 22 (50%) were urinary catheter associated. There were 10 patients with E. coli bacteraemia caused by procedures, seven genitourinary or biliary tract instrumentation and three postgastrointestinal surgery. Conclusion E. coli bacteraemias related to urosepsis could have been prevented by better empirical treatment and targeted prophylaxis. Urinary catheter quality improvement programmes should contribute to a further reduction. For patients undergoing high-risk urinary or biliary tract procedures or device manipulation, we advocate single-dose amikacin prophylaxis.Keywords
This publication has 14 references indexed in Scilit:
- Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitalsClinical Microbiology and Infection, 2016
- Urethral (indwelling or intermittent) or suprapubic routes for short-term catheterisation in hospitalised adultsCochrane Database of Systematic Reviews, 2015
- d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trialWorld Journal of Urology, 2013
- Outcomes in UK patients with hospital-acquired bacteraemia and the risk of catheter-associated urinary tract infectionsPostgraduate Medical Journal, 2013
- Methenamine hippurate for preventing urinary tract infectionsCochrane Database of Systematic Reviews, 2012
- Reduction of Inappropriate Urinary Catheter Use at a Veterans Affairs Hospital Through a Multifaceted Quality Improvement ProjectClinical Infectious Diseases, 2011
- Oestrogens for preventing recurrent urinary tract infection in postmenopausal womenCochrane Database of Systematic Reviews, 2008
- Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coliJournal of Infection, 2007
- Cranberries for preventing urinary tract infections2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987